Macugen maintenance

Article

Macugen maintenance

OSI Pharmaceuticals and Pfizer have announced the initiation of a Phase IV trial to explore the safety and efficacy of Macugen (pegaptanib sodium injection) as a maintenance therapy for patients who have received prior wet age related macular degeneration (AMD) treatment and experienced improvement in their condition.

LEVEL (evaLuation of Efficacy and safety in maintaining Visual acuity with sEquential treatment of neovascuLar AMD), is an open label, multicentre trial, open to subjects who have had at least one, but no more than three, treatments for wet AMD within 30 to 120 days prior to the study. The 54-week trial comprises of up to 1,000 patients at 100 sites across the USA. Macugen will be administered once every six weeks for 48 weeks, booster treatment may be employed if the investigator believes macular disease has progressed.

The primary endpoint is the percentage of patients who remain at baseline vision or gain (more than or equal to 0 lines) vision from baseline to 54 weeks. Secondary endpoints include the percentage of patients maintaining or gaining one, two and three lines of visual acuity at week 54 compared with pre-enrolment baseline vision; mean change of visual acuity from baseline to week 54; percentage of subjects losing less than three lines of vision at week 54; and anatomical outcomes on fluorescein angiography and optical coherence tomography.

Macugen is already an approved treatment for wet AMD in North America, Europe, Brazil, Argentina, Peru, Pakistan and The Philippines. This study hopes to demonstrate that the drug can continue to be effective over an extended period of time.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.